Cu entuziasm și profesionalism, Dr. Dan CĂLUGĂRU a format o echipă bine pregătită, care având la dispoziție tehnică medicală performantă, ajută la rezolvarea problemelor oftalmologice, punând întotdeauna accent pe confortul și siguranța pacienților, oferind servicii oftamologice complete la standarde înalte de calitate, atât prin experiența profesională cât și ca nivel al dotării cu aparatură. Echipa beneficiază de suportul și experiența Prof. Univ. Dr. Mihai Călugăru.
Management of the open angle glaucoma in patients with central/hemicentral retinal vein occlusions
March 2019, Volume 12, Issue 3, pp.436-441
Central serous chorioretinopathy in elderly subjects: angiographic and tomographic characteristics
February 2019, Volume 11, Issue 02, pp.1614-1615
Conbercept for Treatment of Neovascular Age-related Macular Degeneration: Results of the Randomized Phase 3 Phoenix Study
February 2019, Volume 198, Pages 262–263
Re: van Dijk et al: Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: The PLACE trial
January 2019, Volume 126, Issue 1, Pages e10–e11
Choroidal thickness changes stratified by outcome in real-world treatment of diabetic macular edema
January 2019, Volume 257, Issue 1, pp. 241–242
Re: Berry et al: Association of Disorganization of Retinal Inner Layers with Ischemic Index and Visual Acuity in Central Retinal Vein Occlusion
January 2019, Volume 3, Issue 1, page e1
Comment on “Intravitreal dexamethasone implants for diabetic macular edema”
December 2018, Volume 11, Issue 12, p. 2029-2032
Anti-VEGF Treatment for Diabetic Macular Edema in a Real-World Clinical Setting
December 2018, Volume 196, p. 208–209
Comment on “Assessment of the long-term visual and anatomical outcomes of ranibizumab to treat neovascular age-related macular degeneration”
November 2018, Volume 11, Issue 11, p. 1884-1886
Clinical Features of Central Serous Chorioretinopathy With Type 1 Choroidal Neovascularization
November 2018, Volume 195, p. 245–246
Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the united states
October 2018, Volume 10, Issue 10, pp.74665-74666
Half-time photodynamic therapy in treatment of chronic central serous chorioretinopathy
October 2018, Volume 10, Issue 10, pp.74701-74702
Re: Li et al.: Long-term Assessment of Macular Atrophy in Patients with Age-Related Macular Degeneration Receiving Anti-Vascular Endothelial Growth Factor
October 2018, Volume 2, Issue 10, p. e13-e14
Guidelines on diabetic eye care. the international council of ophthalmology recommendations for screening, follow-up, referral, and treatment based on resource settings
September 2018, Volume 8, Issue 9, pp. 22645-22646
Vision Outcomes Following Anti–Vascular Endothelial Growth Factor Treatment of Diabetic Macular Edema in Clinical Practice
September 2018, Volume 193, p. 253–254
Comment on “Management strategies in malignant glaucoma secondary to antiglaucoma surgery”
August 2018, Volume 11, Issue 8, p. 1433-1434
Correspondence
August 2018, Volume 38, Issue 8, p. e69–e71
What We Have Learned From the Ocular Hypertension Treatment Study
August 2018, Volume 192, p. 248–249
The fate of eyes with wet AMD beyond 4 years of anti-VEGF therapy
August 2018, Volume 256, Issue 8, pp. 1551–1552
Clinical characteristics of chronic central serous chorioretinopathy patients with insufficient response to reduced-settings photodynamic therapy
July, 2018, Volume 10, Issue 7, pp. 71192-71193
Sustained benefits from ranibizumab for central retinal vein occlusion with macular edema: 24-month results of the crystal study
July 2018, Volume 10, Issue 7, pp. 71828-71829
Ocular hypertension in patients with central/hemicentral retinal vein occlusions: cumulative prevalence and management
July 2018, Volume 11, Issue 7, pp. 1173-1178
Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success
July 2018, Volume 256, Issue 7, pp. 1353–1354
Bun venit!
În clinica noastră se tratează peste 3000 de pacienți anual, număr în permanentă creștere, având în vedere progresul științific și tehnic de care echipa Dr. Călugăru este mereu preocupată.
Echipamentele noaste sunt furnizate de către producători consacrați în domeniu: Alcon (S.U.A), Bausch & Lomb (SUA), Blanco (Germania), Brumaba (Germania), Carl Zeiss Meditec (Germania), Spacelabs (S.U.A), Getinge (Suedia), Tomey (Japonia), Melag (Germania), Nidek (Japonia), Briot (Belgia).
Pentru operațiile de reducere a dioptriilor cu laser excimer (Lasek, Prk) nu este nevoie de analize. Pentru toate celelalte intervenții chirurgicale analizele sunt obligatorii.
Analizele necesare pentru operație:
- Hemoleucograma
- Coagulograma
- Glicemie
- Uree
- VSH
- AST
- ALT
- Bilirubina totală
- HVB
- HVC
- HIV
- Consult cardiologic
- EKG
Pentru a reuși vindecarea unui număr cât mai mare de pacienți echipa Dr. Călugăru colaborează cu mai mulți medici specializați în oftalmologie, opticieni și optometriști, cât și cu medicii de familie din zonele învecinate.